INSCoV-600K(1) is a potent small molecule inhibitor targeting the SARS-CoV-2 main protease (3CLpro/Mpro), a key enzyme for viral replication. It has demonstrated promising antiviral activity in both in vitro enzymatic assays and cellular infection models, supporting its research potential for developing COVID-19 therapeutics.